Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Neurofibromatosis 1, Plexiform Neurofibroma (PN)
In brief
A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.
Key facts
- Study ID
- NCT04924608
- Run by
- AstraZeneca
- People needed
- 145
- Starts
- 2021-11-19
- Expected to finish
- 2029-02-15
- Last updated by the study team
- 2026-03-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Gainesville, Florida, United States
- Research Site — Rockville, Maryland, United States
- Research Site — St Louis, Missouri, United States
- Research Site — Commack, New York, United States
- Research Site — Melbourne, Australia
- Research Site — St Leonards, Australia
- Research Site — Porto Alegre, Brazil
- Research Site — Ribeirão Preto, Brazil
- Research Site — São Paulo, Brazil
- Research Site — Toronto, Ontario, Canada
- Research Site — Montreal, Quebec, Canada
- Research Site — Beijing, China
- Research Site — Beijing, China
- Research Site — Guangzhou, China
- Research Site — Shenyang, China
- Research Site — Créteil, France
- Research Site — Lyon, France
- Research Site — Toulouse, France
- Research Site — Hamburg, Germany
- Research Site — Tübingen, Germany
- Research Site — Würzburg, Germany
- Research Site — Milan, Italy
- Research Site — Naples, Italy
- Research Site — Roma, Italy
- Research Site — Minatoku, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.